home.html home.html
    • corporation_overview.html corporation_overview.html
    • press_releases.html press_releases.html
    • investors_overview.html investors_overview.html
    • los_angeles_california.html los_angeles_california.html
    • contact_us.html contact_us.html
    • chaperone_overview.html chaperone_overview.html
    • technologies_overview.html technologies_overview.html
    • therapeutics_overview.html therapeutics_overview.html

    •  

    Chaperone Co-Induction
    CytRx owns three clinical-stage compounds based on its small molecule "molecular chaperone" co-induction technology, as well as a targeted library of 500 small molecule drug candidates that may be used to screen for new drug candidates. The three small molecule drugs (arimoclomol, iroxanadine and bimoclomol) provide cellular protection from abnormal proteins by activating molecular "chaperone" proteins that can repair or degrade the damaged proteins that are believed to cause many diseases, including ALS and diabetes.